Liquid Biopsy Market Size Is Anticipated To Reach US$ 3,535.1 Million at a CAGR of 19.3% By 2027
The global liquid biopsy market is estimated to accumulate over US$ 3,535.1 million, in terms of value, by the end of 2027.
Global Liquid Biopsy Market
A liquid biopsy is a simple, non-invasive technique that enables clinicians to discover a range of information about a tumor, with the help of a blood sample. Some of the commercially available liquid biopsy tests for cancer are Cologurad, Guardant360, Oncotype SEQ Liquid Select, and Target Selector liquid biopsy assays. A liquid biopsy test helps detect epidermal growth factor receptor (EGFR) gene mutations, which are evident in non-small cell lung cancer (NSCLC). The process requires only 5 milliliters of blood and is way quicker than a surgical biopsy. The blood sample is processed to get 2 milliliters of plasma, which is then analyzed for determining the tumor DNA. The potential of liquid biopsies to detect disease progression or treatment resistance long before it would trigger the clinical symptoms or appear on imaging scans is a major factor driving the growth of the global liquid biopsy market.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/1223
Tissue samples removed for biopsy many not show all mutations as cancer has multiple genetic mutations, whereas liquid biopsies offer an improved chance of detecting these genetic changes. Moreover, the efficiency of liquid biopsy to improve progression and survival rates in cancer is major factor driving growth of the market. However, in December 2017, two Johns Hopkins prostate cancer researchers found differences in the results from two different liquid biopsy providers and such inconsistencies in results may hinder the growth of the market.
Rising implementation of liquid biopsy owing to its advantages over the conventional biopsy expected to boost the liquid biopsy market growth
Liquid biopsy offers efficient disease management, as well as non-invasive prenatal testing (NIPT). NIPT enables the diagnosis of potential risks of developing chromosomal abnormalities, such as Edwards’s syndrome, Down syndrome, and X and Y chromosome abnormalities. Liquid biopsy offers a complete genetic profile of the patient by providing the DNA for more than one tumor. The process is non-invasive and provides no biases in results, owing to heterogeneity of the tumor tissues. Moreover, the process requires small amount of sample and is cost and time effectiveness. Furthermore, the varied applications of liquid biopsy for the diagnosis of non-small cell lung cancer (NSCLC), breast cancer, coronary heart disease, prostate cancer, and others, is expected to propel the growth of the global market. As per a new study published in Oncology Journal in January 2018, the liquid biopsy combo involving exosomal RNA and cell-free DNA (cfDNA) improved the sensitivity of epidermal growth factor mutations in NSCLC. Furthermore, OncoCyte Corporation presented positive data from its breast cancer diagnostic test study – which was conducted in December 2017 – at the San Antonio Breast Cancer Symposium.
The global liquid biopsy market was valued at US$ 1,824.7 million in 2016 and is expected to witness a robust CAGR of 18.3% over the forecast period (2017–2025).
Manufacturers are focusing on the development of new tests, and this is expected to bolster the global liquid biopsy market growth in the near future
Some well-known players operating in the liquid biopsy market include Illumina, Inc., Roche AG, Natera, Inc., Laboratory Corporation of America Holdings (LabCorp), Qiagen N.V., Thermo Fisher Scientific Inc., Exact Sciences Corp., Biocept, Inc., Genomic Health, Inc., Guardant Health, TrovaGene Inc., CareDx Inc., Adaptive Biotechnologies Corporation, and Biocartis SA.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1223
Numerous established, as well as small players participating in the global liquid biopsy market are actively focusing on research and development of new methods of liquid biopsy through collaborations. For instance, Biodesix, a U.S.-based company, developed a novel way of extract circulating RNA from plasma in November 2017, in collaboration with Norgen Biotek. Moreover, Precipio, a U.S.-based organization, entered into a merger agreement with Transgenomic in 2017, for commercializing ICE COLD PCR (ICP) for liquid biopsies, which preferentially enriches mutant DNA sequences over wild-type DNA through selective amplification. HaploX Biotechnology, a China-based company, raised up to US$ 32 million in financing in January 2018, in order to integrate the liquid biopsy technology, artificial intelligence, and gene sequencing.
Furthermore, in May 2017, Guardant Health, Inc. raised US$ 360 million to create cancer blood tests to deploy its test for 1 million people over the next five years. Guardant Health and MD Anderson Cancer Center launched liquid biopsy partnership, in February 2017, under which Guardant is expected to help MD Anderson to build multiple on-site liquid biopsy centers. Guardant Health announced broad, long term alliance with Pfizer Oncology to support multiple clinical programs with its Guardant360 assay, in June 2017. Moreover, Guardant Health announced that it entered into separate agreements with AstraZeneca, Merck, Merck KGaA, and Darmstadt in January 2017 to develop 500 plus gene liquid biopsy panel to speed up clinical trials and drug development. Natera collaborated with Baylor Genetics to develop a non-invasive prenatal test, Vistara, in May 2017, which aided in detecting de novo mutations in single gene disorders.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire